THE ACTIVE PHARM · EST. 2024

The Active Pharm

The Science of Human Potential

SINGLE PEPTIDE CATALOG

VOLUME II · SINGLE AGENTS

TWENTY-FIVE COMPOUNDS

Contents

Twenty-Five single agents, organized by pharmacological function. Each title links to its full profile.

Semaglutide

The incretin signal for weight and glucose control.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

GLP-1 RECEPTOR AGONIST

01
HOW IT WORKS

Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying, while signaling satiety in the hypothalamus to reduce appetite and caloric intake.

02
WEIGHT LOSS

Produces substantial, sustained weight loss in clinical trials.

03
GLYCEMIC CONTROL

Lowers blood glucose and HbA1c with low hypoglycemia risk.

MOLECULAR FORMULA

GLP-1

receptor agonist

$C_{187}H_{291}N_{45}O_{59}$

MW ≈ 4,113.6 Da

5 MG / 2 ML VIAL

GLP-1 Receptor Agonist

04
PAIRS WELL WITH

Ipamorelin · preserves lean mass during weight loss

Tesamorelin · visceral fat and lean-mass support

AOD-9604 · enhanced fat metabolism

Complementary agents commonly combined in clinical protocols.

05
CARDIOMETABOLIC

Associated with improved cardiovascular and metabolic markers.

METABOLIC & FAT LOSS

SAFETY NOTES

Generally well tolerated. The most common effects are gastrointestinal: nausea, vomiting, diarrhea, or constipation, usually transient and tending to ease over time. Less common concerns include gallbladder issues and pancreatitis. Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. Because rapid weight loss can include lean mass, resistance training and muscle-preserving agents are commonly paired.

Tirzepatide

Two incretin pathways, activated at once.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

DUAL GIP AND GLP-1 RECEPTOR AGONIST

01
HOW IT WORKS

Co-activates GIP and GLP-1 receptors to amplify insulin release, suppress glucagon, slow gastric emptying, and reduce appetite, enhancing weight loss and glycemic control beyond GLP-1 alone.

02
WEIGHT LOSS

Among the largest weight reductions reported in incretin trials.

03
GLYCEMIC CONTROL

Strong reductions in blood glucose and HbA1c.

MOLECULAR FORMULA

GLP-1·GIP

dual receptor agonist

$C_{225}H_{348}N_{48}O_{68}$

MW ≈ 4,813.5 Da

10 MG / 2 ML VIAL

Dual GIP and GLP-1 Receptor Agonist

04
PAIRS WELL WITH

Ipamorelin · preserves lean mass during weight loss
Tesamorelin · visceral fat and lean-mass support
AOD-9604 · enhanced fat metabolism

Complementary agents commonly combined in clinical protocols.

05
DUAL INCRETIN

Engages both GIP and GLP-1 pathways for an amplified effect.

METABOLIC & FAT LOSS

SAFETY NOTES

Generally well tolerated. Gastrointestinal effects (nausea, diarrhea, constipation) are most common and tend to ease over time. Less common concerns include gallbladder issues and pancreatitis. Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. As with any rapid weight loss, lean-mass loss is a concern.

AOD-9604

The fat-loss fragment of growth hormone.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

MODIFIED HGH 176-191 FRAGMENT

01
HOW IT WORKS

Stimulates beta-adrenergic receptors on fat cells to release stored triglycerides while blocking new fat formation, without touching the growth hormone or insulin pathways.

02
FAT REDUCTION

Targets abdominal and visceral fat for reduction.

03
ANTI-LIPOGENIC

Inhibits new fat formation without hormonal load.

MOLECULAR STRUCTURE



$C_{78}H_{125}N_{23}O_{23}S_2$

MW ≈ 1,817.1 Da

10 MG / 5 ML VIAL

Modified HGH 176-191 Fragment

04
PAIRS WELL WITH

GLP therapy · complements incretin-driven fat loss
5-Amino-1MQ · energy expenditure
MOTS-c · metabolic

Complementary agents commonly combined in clinical protocols.

05
JOINT SUPPORT

Offers joint and anti-inflammatory support.

METABOLIC & FAT LOSS

SAFETY NOTES

A high safety profile in clinical trials: non-toxic, non-immunogenic, and non-hormonal, with no significant reported side effects and no suppression of natural growth hormone or insulin function. Effects appear only with consistent use over two to three months; a single month is generally insufficient for noticeable fat loss.

5-Amino-1MQ

Releasing the brake on metabolism.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

NNMT ENZYME INHIBITOR

01
HOW IT WORKS
Inhibits the enzyme NNMT to regulate cellular NAD+ metabolism, shifting signaling toward greater energy expenditure and metabolic efficiency in fat tissue rather than altering hormones or appetite.

02
METABOLIC EFFICIENCY
Supports healthy metabolism, energy use, and reduced fat accumulation.



MW ≈ 286.1 Da

10 MG / 5 ML VIAL

NNMT Enzyme Inhibitor

03
PAIRS WELL WITH
AOD-9604 · fat metabolism
MOTS-c · mitochondrial
NAD+ · cellular energy

Complementary agents commonly combined in clinical protocols.

04
ENZYMATIC PATHWAY
Acts on the NNMT enzyme rather than on hormones.

METABOLIC & FAT LOSS

SAFETY NOTES
As an NNMT inhibitor used in experimental metabolic protocols, 5-Amino-1MQ is less standardized than many peptides. Providers should watch for stimulation-type effects such as restlessness or insomnia, GI upset, headache, or appetite changes. Use caution in patients with significant metabolic disease until tolerance and monitoring are established.

Sermorelin

Growth hormone, prompted not replaced.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

GROWTH HORMONE-RELEASING HORMONE ANALOG

01
HOW IT WORKS

Binds pituitary GHRH receptors to release the body's own growth hormone and downstream IGF-1, working with the natural nighttime rhythm and preserving normal pituitary feedback.

02
GH OUTPUT

Raises natural growth hormone output without direct replacement.

03
SLEEP & RECOVERY

Improves sleep depth, recovery, and tissue regeneration.

MOLECULAR STRUCTURE



$C_{149}H_{246}N_{44}O_{42}S$

MW ≈ 3,357.9 Da

10 MG / 5 ML VIAL

Growth Hormone-Releasing Hormone Analog

04
PAIRS WELL WITH

GLP therapy · lean-mass support during weight loss
Ipamorelin · complementary GH pulse
BPC-157 · recovery

Complementary agents commonly combined in clinical protocols.

05
BODY & SKIN

Supports lean mass, body composition, and skin quality.

GROWTH HORMONE & ANABOLIC SIGNALING

SAFETY NOTES

Sermorelin carries a strong safety profile. Side effects are generally mild: transient flushing, dizziness, injection-site irritation, or headache, with occasional increased appetite or vivid dreams from heightened growth hormone output. It is typically administered subcutaneously at night to align with circadian release, and effects accumulate over several weeks as IGF-1 rises gradually.

Tesamorelin

Targeted reduction of visceral fat.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

STABILIZED GROWTH HORMONE-RELEASING HORMONE ANALOG

01
HOW IT WORKS
A stabilized GHRH analog that drives pulsatile growth hormone and IGF-1; a hexenoic-acid group resists breakdown for higher, sustained release and targeted visceral-fat loss.

02
VISCERAL FAT
Significantly reduces visceral adipose tissue.

03
LEAN MASS
Supports lean mass and body recomposition.

MOLECULAR STRUCTURE



$C_{220}H_{366}N_{72}O_{67}S$

MW ≈ 5,123.8 Da

10 MG / 5 ML VIAL

Stabilized Growth Hormone-Releasing Hormone Analog

04
PAIRS WELL WITH
GLP therapy · lean-mass support during weight loss
Ipamorelin · GH pulse
MOTS-c · metabolic

Complementary agents commonly combined in clinical protocols.

05
METABOLIC MARKERS
May improve insulin sensitivity and lipid profiles.

GROWTH HORMONE & ANABOLIC SIGNALING

SAFETY NOTES

Well studied with a strong safety profile. Common effects are injection-site irritation, mild edema, muscle stiffness, or joint discomfort tied to elevated growth hormone. It does not suppress natural production and does not cause acromegaly when used appropriately. Use under supervision in patients with diabetes, active malignancy, or cardiovascular disease.

Ipamorelin

A clean pulse of growth hormone.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

SELECTIVE GROWTH HORMONE SECRETAGOGUE

01
HOW IT WORKS

Activates pituitary GHS-R, the ghrelin receptor, for a clean, pulsatile growth hormone release without the broad hormonal disturbance of less selective agents.

02
MUSCLE & RECOVERY

Supports lean muscle and recovery from training or injury.

03
SLEEP & METABOLISM

Improves sleep quality and healthy fat metabolism.

MOLECULAR STRUCTURE



$C_{38}H_{49}N_9O_5$

MW ≈ 711.9 Da

10 MG / 5 ML VIAL

Selective Growth Hormone Secretagogue

04
PAIRS WELL WITH

GLP therapy · preserves lean mass during weight loss
Tesamorelin · visceral fat
BPC-157 · recovery

Complementary agents commonly combined in clinical protocols.

05
SELECTIVE ACTION

Raises GH and IGF-1 signaling while sparing cortisol and prolactin.

GROWTH HORMONE & ANABOLIC SIGNALING

SAFETY NOTES

Generally well tolerated. Possible effects include transient flushing, headache, lightheadedness, water retention, and increased appetite. Because it raises growth hormone and IGF-1 signaling indirectly, use clinician oversight in patients with diabetes or insulin resistance, active malignancy, or significant edema or cardiovascular risk.

IGF-1 LR3

Growth hormone's anabolic message, delivered directly.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

INSULIN-LIKE GROWTH FACTOR 1, LONG ARG3

01
HOW IT WORKS

Binds the IGF-1 receptor to activate PI3K/Akt and MAPK signaling for protein synthesis and cell growth; resists binding proteins for a long, sustained anabolic signal.

02
LEAN MUSCLE

Increases lean muscle through enhanced protein synthesis.

03
RECOVERY & REPAIR

Accelerates recovery and supports tendon, ligament, and connective-tissue repair.

MOLECULAR STRUCTURE



$C_{390}H_{625}N_{111}O_{115}S_5$

MW ≈ 8,869.3 Da

10 MG / 5 ML VIAL

Insulin-like Growth Factor 1, Long Arg3

04
PAIRS WELL WITH

Ipamorelin · GH pulse
BPC-157 · tissue repair
TB-500 · connective tissue

Complementary agents commonly combined in clinical protocols.

05
NUTRIENT UPTAKE

Improves nutrient partitioning and cellular hydration.

GROWTH HORMONE & ANABOLIC SIGNALING

SAFETY NOTES

A highly potent compound that requires careful clinical oversight. Excess can cause hypoglycemia, organ enlargement, or accelerated growth of existing malignancy given its strong proliferative action. It should not be used by anyone with a history of cancer without physician clearance, and blood glucose should be monitored throughout use.

MOTS-c

A signal written in mitochondrial DNA.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

MITOCHONDRIAL-DERIVED PEPTIDE

01
HOW IT WORKS

Encoded by mitochondrial DNA, MOTS-c activates AMPK, the cell's metabolic master switch, promoting fat oxidation, glucose use, and mitochondrial biogenesis, and acting as a mitokine to distant tissues.

02
GLUCOSE CONTROL

Improves insulin sensitivity and glucose control.

03
BODY COMPOSITION

Reduces visceral fat and supports body composition.

MOLECULAR STRUCTURE



$C_{49}H_{75}N_{17}O_{15}$

MW ≈ 1,142.2 Da

10 MG / 5 ML VIAL

Mitochondrial-Derived Peptide

04
PAIRS WELL WITH

NAD+ · cellular energy
AOD-9604 · fat metabolism
Tesamorelin · metabolic

Complementary agents commonly combined in clinical protocols.

05
ENDURANCE

Enhances endurance and buffers fatigue.

MITOCHONDRIAL & CELLULAR ENERGY

SAFETY NOTES

A strong safety profile in preclinical and limited human research. Side effects are rare and may include temporary fatigue or mild injection-site irritation. Because it modulates key metabolic pathways, use caution alongside blood-sugar-lowering medications to avoid hypoglycemia.

NAD+

The coenzyme behind cellular energy.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

NICOTINAMIDE ADENINE DINUCLEOTIDE

01
HOW IT WORKS

A coenzyme central to ATP production and the substrate for sirtuins and PARPs; restoring it reactivates longevity pathways, improves mitochondrial efficiency, and lowers inflammation.

02
CELLULAR ENERGY

Increases mitochondrial energy production.

03
CLARITY & MOOD

Supports mental clarity, memory, and mood.

MOLECULAR STRUCTURE



$C_{21}H_{27}N_7O_{14}P_2$

MW ≈ 663.4 Da

1000 MG / 5 ML VIAL

Nicotinamide Adenine Dinucleotide

04
PAIRS WELL WITH

MOTS-c · mitochondrial
Epitalon · longevity
Thymosin Alpha-1 · systemic repair

Complementary agents commonly combined in clinical protocols.

05
LONGEVITY

Promotes cellular repair and may extend healthspan via sirtuins.

MITOCHONDRIAL & CELLULAR ENERGY

SAFETY NOTES

Well tolerated when used appropriately. Rapid infusion can cause transient flushing, chest tightness, nausea, or warmth; slower administration minimizes these. It is non-toxic and non-suppressive and suitable for long-term use.

SS-31

Stabilizing the engine of the cell.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

CARDIOLIPIN-TARGETING TETRAPEPTIDE

01
HOW IT WORKS

Selectively binds cardiolipin in the inner mitochondrial membrane, protecting the cristae and electron transport chain; this improves ATP production and reduces reactive-oxygen-species leakage in stressed or aging cells.

02
CELLULAR ENERGY

Improves mitochondrial ATP production in stressed tissue.

03
OXIDATIVE STRESS

Reduces oxidative stress by limiting reactive oxygen species.

MOLECULAR STRUCTURE



$C_{32}H_{49}N_9O_5$

MW ≈ 639.8 Da

50 MG / 5 ML VIAL

Elamipretide
Cardiolipin-Targeting
Tetrapeptide

04
PAIRS WELL WITH

NAD+ · cellular energy
MOTS-c · mitochondrial signaling
Epitalon · longevity

Complementary agents commonly combined in clinical protocols.

05
ORGAN SUPPORT

Supports cardiac, renal, and neuronal function in mitochondrial dysfunction.

MITOCHONDRIAL & CELLULAR ENERGY

SAFETY NOTES

Generally well tolerated in clinical study, with injection-site reactions (redness, irritation) the most common effect. Other reported effects are mild and may include headache or GI upset. It is non-suppressive and has shown a favorable profile across trials, though long-term human data are still developing. Use under clinician oversight in patients with significant cardiac or renal disease.

Glutathione

The body's master antioxidant.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

MASTER ANTIOXIDANT

01
HOW IT WORKS
Cycles between reduced and oxidized forms to neutralize reactive oxygen species and regenerate other antioxidants; in the liver it conjugates toxins for elimination and supports mitochondrial and immune function.

02
ANTIOXIDANT DEFENSE
Neutralizes free radicals and lowers oxidative stress.

03
DETOXIFICATION
Supports liver detoxification and clearance of toxins.

MOLECULAR STRUCTURE



$C_{10}H_{17}N_3O_6S$

MW ≈ 307.3 Da

2000 MG / 10 ML · 6000 MG / 30 ML VIAL

Gamma-Glutamyl-Cysteinyl-Glycine
Master Antioxidant

04
PAIRS WELL WITH
NAD+ · cellular energy
SS-31 · mitochondrial protection
Epitalon · antioxidant longevity

Complementary agents commonly combined in clinical protocols.

05
SKIN & RECOVERY
Promotes skin brightness and supports cellular recovery.

MITOCHONDRIAL & CELLULAR ENERGY

SAFETY NOTES
Glutathione is well tolerated and naturally present in the body. Injectable use is generally safe, with occasional mild effects such as transient lightheadedness or injection-site irritation. Rare reports of skin lightening beyond the intended area exist with prolonged intravenous use. Patients with asthma should use caution, as inhaled forms have been associated with bronchospasm. Sterility and quality of the compounded preparation are essential.

BPC-157

Repair, carried through every tissue.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

BODY PROTECTION COMPOUND

01
HOW IT WORKS

Drives healing through several pathways at once: upregulates growth-hormone receptors in tendon fibroblasts and activates the VEGFR2-Akt-eNOS axis for angiogenesis and cell migration.

02
TISSUE REPAIR

Accelerates repair of tendon, ligament, muscle, skin, and bone in animal models.

03
GUT PROTECTION

Protects and stabilizes the gastrointestinal lining; supports fistula and colitis healing.

MOLECULAR STRUCTURE



$C_{62}H_{98}N_{16}O_{22}$

MW ≈ 1,419.6 Da

10 MG / 5 ML VIAL

Pentadecapeptide
Body Protection Compound

04
PAIRS WELL WITH

TB-500 · soft-tissue synergy
GHK-Cu · skin and repair
KPV · gut barrier

Complementary agents commonly combined in clinical protocols.

05
NEURAL RECOVERY

Counters neural injury and supports recovery after traumatic insult.

TISSUE REPAIR & RECOVERY

SAFETY NOTES

Extremely well tolerated across human and animal models, with no known toxicity at therapeutic levels and no suppression of natural healing. Infrequent effects include nausea, mild headache, transient dizziness, or injection-site irritation. Use caution in patients on anticoagulant or antihypertensive medications, as BPC-157 may influence vascular healing and blood flow. Clinical evidence in humans remains limited.

TB-500

Mobility and repair, signaled system-wide.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

THYMOSIN BETA-4 ACTIVE FRAGMENT

01
HOW IT WORKS

Regulates actin to upregulate cell motility, differentiation, and angiogenesis; raises VEGF and matrix metalloproteinases to build vessels and remodel tissue, and lowers inflammatory cytokines.

02
INJURY RECOVERY

Accelerates recovery from muscle, tendon, and ligament injury.

03
FLEXIBILITY

Improves flexibility and reduces connective-tissue stiffness.

MOLECULAR STRUCTURE



$C_{212}H_{350}N_{56}O_{78}S$

MW ≈ 4,963.5 Da

10 MG / 5 ML VIAL

Thymosin Beta-4 Active Fragment

04
PAIRS WELL WITH

BPC-157 · soft-tissue synergy
GHK-Cu · skin and repair
IGF-1 LR3 · anabolic repair

Complementary agents commonly combined in clinical protocols.

05
VASCULAR REPAIR

Supports angiogenesis and cardiovascular repair.

TISSUE REPAIR & RECOVERY

SAFETY NOTES

Generally well tolerated. Mild effects may include fatigue, lightheadedness, or transient flu-like symptoms; injection-site reactions are rare. No known toxicity or carcinogenicity is associated with TB-500, and it does not suppress natural hormone production.

GHK-Cu

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

The copper signal behind collagen, skin, and hair renewal.

COPPER TRIPEPTIDE

01
HOW IT WORKS

Delivers bioavailable copper and drives collagen, elastin, and glycosaminoglycan synthesis; at the genetic level it resets hundreds of repair-related genes and raises antioxidant enzymes.

02
SKIN & COLLAGEN

Improves elasticity, softens fine lines, and lightens hyperpigmentation.

03
WOUND HEALING

Accelerates wound, burn, and ulcer repair; supports post-surgical recovery.

MOLECULAR STRUCTURE



$C_{14}H_{24}N_6O_4 \cdot Cu$

MW ≈ 403.9 Da

50 MG / 5 ML VIAL

Glycyl-Histidyl-Lysine Copper Tripeptide

04
PAIRS WELL WITH

BPC-157 · tissue repair
TB-500 · connective tissue
Sermorelin · skin and collagen

Complementary agents commonly combined in clinical protocols.

05
HAIR & FOLLICLE

Stimulates follicular repair for hair regrowth and thickening.

TISSUE REPAIR & RECOVERY

SAFETY NOTES

Extremely well tolerated in both topical and injectable forms, with no major side effects documented in clinical or preclinical use. Mild injection-site irritation, headache, or fatigue can occur in sensitive patients. Because GHK-Cu binds copper, monitor copper levels during extended systemic use; patients with copper-metabolism disorders or active malignancy should use it only under clinician supervision.

Thymosin Alpha-1

Recalibrating immune intelligence.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

IMMUNOREGULATORY PEPTIDE

01
HOW IT WORKS
A biological response modifier that activates T-lymphocytes and natural killer cells and raises interleukin-2 and interferon-gamma, while calming pro-inflammatory cytokines to rebalance immunity.

02
IMMUNE DEFENSE
Strengthens immune defense during infection.

03
SURVEILLANCE
Enhances immune surveillance of abnormal cells.

MOLECULAR STRUCTURE



$C_{129}H_{215}N_{33}O_{55}$

MW ≈ 3,108.3 Da

10 MG / 5 ML VIAL

Immunoregulatory Peptide

04
PAIRS WELL WITH
LL-37 · antimicrobial
KPV · anti-inflammatory
BPC-157 · recovery

Complementary agents commonly combined in clinical protocols.

05
INFLAMMATION
Calms inflammation in autoimmune conditions.

INFLAMMATION & IMMUNE DEFENSE

SAFETY NOTES
An excellent safety profile with few adverse effects even in long-term use. Mild effects may include fatigue, slight injection-site irritation, or transient headache. Acting as a biologic normalizer, it does not overstimulate the immune system and may be used preventively or acutely.

KPV

Inflammation, quieted at the source.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

ALPHA-MSH FRAGMENT

01
HOW IT WORKS

Inhibits activation of NF-kB, the transcription factor that triggers inflammatory cytokine production. The result is reduced excess inflammation with normal immune defense preserved, supporting healthy inflammatory responses throughout the body.

02
GUT BARRIER

Promotes gastrointestinal and gut-barrier health.

MOLECULAR STRUCTURE



$C_{17}H_{32}N_6O_4$

MW ≈ 384.5 Da

10 MG / 5 ML VIAL

Lysine-Proline-Valine alpha-MSH Fragment

03
PAIRS WELL WITH

BPC-157 · gut lining and tissue repair
Thymosin Alpha-1 · immune modulation
LL-37 · antimicrobial support

Complementary agents commonly combined in clinical protocols.

04
SKIN & TISSUE

Calms skin inflammation and assists tissue recovery.

INFLAMMATION & IMMUNE DEFENSE

SAFETY NOTES

Generally well tolerated. Possible effects are usually mild: transient headache, fatigue, GI upset, or injection-site irritation in sensitive patients. Because it modulates inflammatory signaling, use caution in patients with highly reactive immune profiles and monitor for unexpected sensitivity.

LL-37

Innate defense, broadly armed.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

CATHELICIDIN-DERIVED ANTIMICROBIAL PEPTIDE

01
HOW IT WORKS

Its cationic, amphipathic structure disrupts microbial membranes for broad-spectrum killing, while recruiting immune cells, tuning cytokines, and promoting angiogenesis and re-epithelialization.

02
BROAD DEFENSE

Broad-spectrum action against bacteria, viruses, and fungi.

03
WOUND REPAIR

Supports wound healing and tissue regeneration.

MOLECULAR STRUCTURE



$C_{204}H_{345}N_{55}O_{46}$

MW ≈ 4,304.3 Da

5 MG / 5 ML VIAL

Cathelicidin-Derived Antimicrobial Peptide

04
PAIRS WELL WITH

Thymosin Alpha-1 · immune modulation
KPV · anti-inflammatory
BPC-157 · recovery

Complementary agents commonly combined in clinical protocols.

05
SKIN & BIOFILM

Calms inflammatory skin conditions and disrupts biofilms.

INFLAMMATION & IMMUNE DEFENSE

SAFETY NOTES

Typically well tolerated but can cause injection-site irritation, flushing, or mild inflammation. Because it stimulates immune activity, use caution in patients with autoimmune disorders or high baseline inflammation. Long-term use is not recommended without provider oversight.

Semax

Focus and neural resilience.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

ACTH(4-10) HEPTAPEPTIDE ANALOG

01
HOW IT WORKS

Inhibits enkephalin breakdown and enhances dopamine and serotonin transmission; raises BDNF, nerve growth factor, and VEGF for neuroplasticity and cerebral blood flow, without raising heart rate.

02
FOCUS & CLARITY

Enhances focus, learning, and mental clarity.

03
DRIVE

Increases dopamine signaling for drive and motivation.

MOLECULAR STRUCTURE



$C_{37}H_{51}N_9O_{10}$

MW ≈ 781.9 Da

10 MG / 5 ML VIAL

ACTH(4-10) Heptapeptide Analog

04
PAIRS WELL WITH

Selank · complementary nootropic

NAD+ · neural energy

Complementary agents commonly combined in clinical protocols.

05
NEUROPROTECTION

Provides neuroprotection after stress, injury, or fatigue.

COGNITIVE FUNCTION & NEUROPROTECTION

SAFETY NOTES

Extremely well tolerated, with minimal reported side effects. Occasional users may notice mild euphoria, nasal irritation, or light sensitivity. It is non-addictive and does not disturb sleep or appetite when used appropriately. Administration is typically intranasal.

Selank

Calm without sedation.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

TUFTSIN-DERIVED HEPTAPEPTIDE

01
HOW IT WORKS

Modulates the GABAergic system, enhancing natural GABA sensitivity and release for calm without sedation; also raises serotonin and dopamine turnover and BDNF expression.

02
ANXIETY & MOOD

Reduces anxiety and tension and improves emotional resilience.

03
FOCUS

Enhances focus and mental clarity.

MOLECULAR STRUCTURE



$C_{33}H_{57}N_{11}O_9$

MW ≈ 751.9 Da

10 MG / 5 ML VIAL

Tuftsin-Derived Heptapeptide

04
PAIRS WELL WITH

Semax · complementary nootropic
DSIP · sleep and stress

Complementary agents commonly combined in clinical protocols.

05
CLEAN PROFILE

Non-sedating and non-habit-forming.

COGNITIVE FUNCTION & NEUROPROTECTION

SAFETY NOTES

A strong safety profile in animal and human studies, with no sedation, withdrawal, or abuse potential. Side effects are rare and may include mild nasal irritation or transient headache in sensitive users. It is typically administered intranasally.

Epitalon

Tuned to the clock of cellular aging.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

PINEAL TETRAPEPTIDE (AEDG)

01
HOW IT WORKS

Activates telomerase to help preserve telomere length, regulates gene expression in stem and neural cells, raises antioxidant enzymes, and helps restore melatonin and circadian rhythm.

02
CELLULAR LONGEVITY

Supports telomere maintenance and cellular longevity.

03
CIRCADIAN RHYTHM

Normalizes circadian rhythm and melatonin production.

MOLECULAR STRUCTURE



$C_{14}H_{22}N_4O_9$

MW ≈ 390.3 Da

10 MG / 5 ML VIAL

Pineal Tetrapeptide (AEDG)

04
PAIRS WELL WITH

NAD+ · longevity pathways
DSIP · sleep
Thymosin Alpha-1 · immune resilience

Complementary agents commonly combined in clinical protocols.

05
ANTIOXIDANT

Provides antioxidant and neuroprotective effects.

LONGEVITY, SLEEP & CIRCADIAN

SAFETY NOTES

A strong safety profile in animal and early human studies, with minimal reported adverse effects. Although telomerase activation raises theoretical concerns about uncontrolled cell growth, available studies suggest Epitalon may suppress rather than promote certain cancers. Long-term use is best approached under clinical supervision.

DSIP

Deep sleep, gently restored.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

DELTA SLEEP-INDUCING PEPTIDE

01
HOW IT WORKS

Enhances slow-wave (delta) sleep and promotes sleep onset without acting as a sedative. It modulates the hypothalamus to balance hormonal rhythms, helps normalize cortisol, and shows antioxidant and neuroprotective activity in the central nervous system.

02
DEEP SLEEP

Enhances deep, restorative sleep and reduces stress-related disturbance.

MOLECULAR STRUCTURE



$C_{35}H_{48}N_{10}O_{15}$

MW ≈ 848.8 Da

10 MG / 5 ML VIAL

Delta Sleep-Inducing Peptide

03
PAIRS WELL WITH

Epitalon · circadian rhythm
Selank · stress and calm
Oxytocin · relaxation

Complementary agents commonly combined in clinical protocols.

04
CIRCADIAN BALANCE

Supports hormonal balance and circadian regulation.

LONGEVITY, SLEEP & CIRCADIAN

SAFETY NOTES

Non-sedating and non-habit-forming. Rare side effects include vivid dreams, headache, or mild grogginess. It should be avoided in patients with epilepsy or severe psychiatric disorders and used only under provider oversight.

PT-141

Desire, restored at its source in the brain.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

MELANOCORTIN AGONIST

01
HOW IT WORKS

Binds melanocortin receptors MC3R and MC4R in the hypothalamus, increasing dopamine release and engaging arousal and reward circuits; the effect is central rather than vascular.

02
DESIRE

Increases libido and sexual desire in both men and women.

03
FUNCTION

Supports erectile function independent of blood-flow mechanics.

MOLECULAR STRUCTURE



$C_{50}H_{68}N_{14}O_{10}$

MW ≈ 1,025.2 Da

10 MG / 5 ML VIAL

Bremelanotide
Melanocortin Agonist

04
PAIRS WELL WITH

Oxytocin · arousal and bonding
Kisspeptin · reproductive hormones

Complementary agents commonly combined in clinical protocols.

05
WHERE PDE5 FAILS

Effective where PDE5 inhibitors are not, with no blood-pressure impact.

SEXUAL & REPRODUCTIVE HEALTH

SAFETY NOTES

Generally well tolerated. Side effects can include facial flushing, headache, nausea, and a transient rise in blood pressure, usually mild; subcutaneous injection carries fewer systemic effects than nasal forms. Not recommended for patients with uncontrolled hypertension or heart disease, or those taking dopamine agonists without clinician oversight.

Oxytocin

The chemistry of bonding.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

NONAPEPTIDE NEUROHORMONE

01
HOW IT WORKS
Binds receptors across the brain and body, modulating dopamine and serotonin to enhance trust and calm, amplifying arousal, and lowering amygdala activity to blunt fear and anxiety.

02
BONDING
Improves emotional bonding and connection.

03
CALM
Reduces anxiety and stress by calming the nervous system.

MOLECULAR STRUCTURE



$C_{43}H_{66}N_{12}O_{12}S_2$

MW ≈ 1,007.2 Da

10 MG / 5 ML VIAL

Nonapeptide Neurohormone

04
PAIRS WELL WITH
PT-141 · desire and arousal
Kisspeptin · hormonal signaling
DSIP · relaxation

Complementary agents commonly combined in clinical protocols.

05
AROUSAL
Enhances arousal and intimacy.

SEXUAL & REPRODUCTIVE HEALTH

SAFETY NOTES
Generally well tolerated when used appropriately. Possible effects include mild headache, flushing, lightheadedness, or temporary emotional sensitivity; higher amounts may rarely cause hypotension or nausea. It should be avoided in pregnancy unless medically indicated. Intermittent use is preferred to avoid receptor desensitization.

Kisspeptin

The upstream switch of reproductive hormones.

THE ACTIVE PHARM
EST. 2024
503A PHARMACY COMPOUNDED

KISS1 FRAGMENT

01
HOW IT WORKS

Activates hypothalamic receptors that trigger GnRH release, driving the pituitary to release LH and FSH, which act on the gonads to support testosterone production and reproductive balance while preserving the body's own feedback.

02
HORMONE SIGNALING

Supports healthy testosterone levels and stimulates natural hormone pathways.

MOLECULAR STRUCTURE



$C_{63}H_{83}N_{17}O_{14}$

MW ≈ 1,302.5 Da

10 MG / 5 ML VIAL

Kisspeptin-10
KISS1 Fragment

03
PAIRS WELL WITH

PT-141 · desire and arousal
Oxytocin · intimacy

Complementary agents commonly combined in clinical protocols.

04
REPRODUCTIVE FUNCTION

Promotes reproductive function and libido.

SEXUAL & REPRODUCTIVE HEALTH

SAFETY NOTES

Generally well tolerated. Possible side effects include headache, flushing, nausea, or mild fatigue. Because it directly influences reproductive hormone signaling, patients with endocrine disorders or hormone-sensitive conditions should use it under clinician guidance.

Disclaimer & Professional Use

FDA Disclosure

These statements have not been evaluated by the Food and Drug Administration. These formulations are not intended to diagnose, treat, cure, or prevent any disease. Results may vary.

Sourcing & Compounding

All peptides and formulations offered by The Active Pharm are compounded exclusively through 503A pharmacies operating under licensed pharmacist oversight, in accordance with applicable state and federal compounding standards.

General Reference

This edition is provided for general educational reference and does not include dosing, titration, or cycling guidance. All dosing and administration decisions must come from the patient's licensed medical provider.

Pairing References

The "Pairs Well With" references describe agents commonly combined in practice and are not treatment recommendations.

Professional Use Notice

By placing an order, the purchaser affirms the following:

Licensure & Eligibility. The purchaser is a licensed medical provider, an authorized medical facility, or an entity operating under a provider's medical license.

Professional Use Only. All products are intended for professional or clinical use. They are made available only to licensed medical providers operating under direct medical oversight.

Responsibility & Oversight. The purchaser accepts full responsibility for the appropriate handling, storage, administration, and use of all products in accordance with their medical licensure, local regulations, and internal protocols. The Active Pharm does not provide diagnosis, treatment recommendations, or clinical guidance. All usage decisions remain solely at the discretion of the treating provider.

COMPOUNDED · 503A PHARMACY NETWORK · CLINICIAN USE ONLY